Browse study websites

Discover. Prevent. Cure.

Menu Fundraise Donate

    Recommended pages

      Do you mean

        351-360 of 10894 results

        Refine search

        The change-makers: how a group of Aboriginal Elders is fighting for housing equity

        A child can’t thrive if they don’t have a roof over their head. Housing shortages, high rates of Aboriginal homelessness and housing insecurity are ...

        Research

        The ARC Centre of Excellence for Children and Families over the Life Course (Life Course Centre or LCC)

        Steve Zubrick SR FASSA, FAAMHS, MSc AM PhD Honorary Emeritus Research Fellow 08 6319 1409 Stephen.zubrick@telethonkids.org.au Honorary Emeritus ...

        Findings

        Findings from the Ngulluk Koolunga Ngulluk Koort (Our Children, Our Heart) Project community forums and focus groups. ...

        News & Events

        McCusker Charitable Foundation grant in support of the Undiagnosed Diseases Program

        Telethon Kids Institute congratulates Prof Gareth Baynam and Dr Timo Lassmann on their grant over three years from the McCusker Charitable Foundation. ...

        Research

        National Hybrid Closed-Loop Outpatient Trial

        Hybrid closed-loop systems are made up of an insulin pump, continuous glucose monitor and a maths program or algorithm. The algorithm collects data ...

        Trans pathways

        ...

        Research

        Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial

        CDKL5 deficiency disorder (CDD) is a rare developmental and epileptic encephalopathy. Ganaxolone, a neuroactive steroid, reduces the frequency of major motor seizures in children with CDD. This analysis explored the effect of ganaxolone on non-seizure outcomes.  ...

        Research

        Patient-advocate-led global coalition adapting fit-for-purpose outcomes measures to assure meaningful inclusion of DEEs in clinical trials

        Existing clinical tools that measure non-seizure outcomes lack the range and granularity needed to capture skills in developmental and epileptic encephalopathy (DEE)-affected individuals who also fall in the severe to profound range of intellectual disability. This effectively excludes those with severe impairments from clinical trials, impeding the ability of sponsors to evaluate disease-modifying therapies. ...

        Research

        Efficacy thresholds and target populations for antiviral COVID-19 treatments to save lives and costs: a modelling study

        In 2023 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was declared endemic, yet hospital admissions have persisted and risen within populations at high and moderate risk of developing severe disease, which include those of older age, and those with co-morbidities. Antiviral treatments, currently only available for high-risk individuals, play an important role in preventing severe disease and hospitalisation within this subpopulation. ...

        Research

        Seasonal malaria chemoprevention and the spread of Plasmodium falciparum quintuple-mutant parasites resistant to sulfadoxine–pyrimethamine: a modelling study

        Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine plus amodiaquine prevents millions of clinical malaria cases in children younger than 5 years in Africa's Sahel region. However, Plasmodium falciparum parasites partially resistant to sulfadoxine-pyrimethamine (with quintuple mutations) potentially threaten the protective effectiveness of SMC. We evaluated the spread of quintuple-mutant parasites and the clinical consequences.  ...

        Page 36 of 1090